InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
4
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by ALCORN HARRY W JR, SVP, Opérations Cliniques. Officer active across 1 company, notably DiaMedica Therapeutics Inc.. Aggregated, 4 filings have been recorded. Breakdown: 4 buys · 0 sell. Total volume traded: €201k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 15 September 2021 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
15,000 shares@ US$3.79730.012% mcap23.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000119:0
Ideal exit: 12 Jun 2022 (T+270)
15,000 shares@ US$3.797323.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000119
Ideal exit: 12 Jun 2022 (T+270)
20,000 shares@ US$3.09220.013% mcap26.1% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000099:0
Ideal exit: 13 May 2022 (T+270)
20,000 shares@ US$3.092226.1% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000099
Ideal exit: 13 May 2022 (T+270)
4 of 4 declarations
About ALCORN HARRY W JR
Harry W. Alcorn Jr. is the Senior Vice President of Clinical Operations at DiaMedica Therapeutics Inc. In this role, he oversees the company's clinical operations, ensuring that clinical trials are conducted efficiently. With experience in the biopharmaceutical sector, he plays a key role in developing new treatments.
